Home

Stent restenosis vs thrombosis

The implementation of bare metal stents and later drug eluting stents (DES) proved to be an important step forward in reducing rates of restenosis after percutaneous coronary intervention. Despite all the benefits of DES, concerns have been raised over their long term safety as especially stent thrombosis sets patients at risk In‐stent thrombosis most commonly presents acutely, with a > 70% incidence of myocardial infarction and > 25% of death. In the case presented here, both the clinical presentation and the angiographic pattern were more consistent with a type III‐IV in‐stent restenosis, but (late) in‐stent thrombosis might have mimicked this angiographic. In-stent thrombosis most commonly presents acutely, with a > 70% incidence of myocardial infarction and > 25% of death. In the case presented here, both the clinical presentation and the angiographic pattern were more consistent with a type III-IV in-stent restenosis, but (late) in-stent thrombosis might have mimicked this angiographic.

Restenosis is not the same as the more dreaded stent thrombosis, the sudden occlusion of a stent from the formation of a blood clot. Stent thrombosis is usually a catastrophe since it often produces sudden and complete blockage of the coronary artery The stent helps keep the artery open. When a part of an artery with a stent gets blocked, it's called in-stent restenosis (ISR). When a blood clot, or thrombus, forms in a part of an artery with a.. Restenosis means that a section of blocked artery that was opened up with angioplasty or a stent has become narrowed again. There are many treatment options for patients who have restenosis after receiving a stent. The first step in treatment is meeting with an experienced cardiac interventionist (a doctor who performs procedures to open up.

The national Swedish Coronary Angiography and Angioplasty Registry (SCAAR) reported an incidence of definite stent thrombosis at 1 year after PCI for any indication of 1.2% for bare metal stents and 0.9% in the older generation of drug-eluting stents. 15 A recently published meta-analysis of 30 studies reported a 1.5% incidence of definite. Comparison of Thrombosis and Restenosis Risk from Stent Length of Sirolimus-Eluting Stents Versus Bare Metal Stents Author links open overlay panel Laura Mauri MD, MSc a A. James O'Malley PhD b Jeffrey J. Popma MD a Jeffrey W. Moses MD c Martin B. Leon MD c David R. Holmes Jr MD d Paul S. Teirstein MD e Donald E. Cutlip MD f Dennis Donahoe MD g. Dr. Sarno noted that the stent thrombosis advantage of new- vs. old-generation DES appeared within the first month. Thereafter, the event rate for new devices increased slightly up to 12 months and then leveled off, while that for older DES rose steadily up to 2 years Abstract and Introduction. Drug-eluting stents reduce the occurrence of in-stent restenosis and the need for subsequent target vessel revascularization when compared with bare-metal stents After a successful procedure, coronary stents can fail to maintain vessel patency due to either restenosis or stent thrombosis. Restenosis is a gradual re-narrowing of the stented segment that occurs mostly between 3 to 12 months after stent placement

Stent restenosis and thrombosis: etiology, treatment, and

The introduction of first-generation drug-eluting stents significantly reduced the rates of restenosis, but at the expense of an increase of late stent thrombosis. Prolonged antithrombotic therapy reduced rates of stent thrombosis, but at the cost of increased bleeding Objective The study sought to compare angiographic and clinical outcomes of new-generation drug-eluting stents (DES) versus drug-coated balloon (DCB) in patients with coronary in-stent restenosis (ISR). Design Meta-analysis using data from randomised trial found by searches on PubMed, the Cochrane Library, ClinicalTrials.gov and websites of major cardiovascular congresses The introduction of drug-eluting stents (DES) led to a significant advancement in the field of interventional cardiology by almost eradicating the problem of in-stent restenosis, the Achilles' heel of bare-metal stents (BMS). Randomized trials have demonstrated the superior efficacy of DES in terms of restenosis 1,2 but has raised a new.

Late thrombosis or in‐stent restenosis

linking specific stent geometry and positioning characteristics with the post-stenting hemodynamic milieu and with the stent's thrombogenicity and pro-restenotic potential, thereby indicating ways to clinical translation. An enhanced understanding of the pathophysiologic role of ESS in restenosis and thrombosis might dictate hemo unclear. Drug-eluting balloons (DEB) offer an alternative to drug-eluting stents (DES) by avoiding risks of stent thrombosis, and by lowering the risks of restenosis asso-ciated with standard balloon angioplasty and bare-metal stents. The objectives were to compare clinical outcomes of DEB versus second-generation DES for the treatment of ISR Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. J Am Coll Cardiol 2020;75:2664-2678. Summary By

Late thrombosis or in-stent restenosis? Hear

Get Info On An Rx Option To Treat & Lower The Risk Of Recurrent DVT/PE Blood Clots. Learn More About The Symptoms Of DVT/PE On An Official Rx Website The two major causes of stent failure are stent thrombosis (ST) and in-stent restenosis (ISR). The incidence of both has reduced considerably in recent years. Current clinical registries and randomized trials with broad inclusion criteria show rates of ST at or <1% after 1 year and ~0.2-0.4% per year thereafter; rates of clinical ISR are 5%.

Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents Laura Mauri, A. James O'Malley, Jeffrey J. Popma, Jeffrey W. Moses, Martin B. Leon, David R. Holmes , Paul S. Teirstein, Donald E. Cutlip, Dennis Donahoe, Richard E. Kunt Stent Restenosis vs Thrombosis #Pathophys #Cardiology #Stent #Thrombosis #Comparison #Restenosis. Contributed by. Dr. Gerald Diaz @GeraldMD. Board Certified Internal Medicine Hospitalist, GrepMed Editor in Chief - Sign up for an account to like, bookmark and upload images to contribute to our community platform

Restenosis After Angioplasty and Stentin

Predictors of restenosis and stent thrombosis in bif ti PCIbifurcation PCI • In-stent restenosis: How frequent and Why? • In-stent restenosis: Stenosis vs. Clinical relevance • Stent thrombosis in bifurcation PCI • Stent thrombosis: Lumen vs. Flow 1 late stent thrombosis occurring mainly when antiplatelet therapy is discontinued in the follow-up. The most recent data show that, in comparison with BMS, there is a small excess of late (> 1 year) stent thrombosis but this is not associated with an increased risk of death or myocardial infarction or all cause mortality trial, testing everolimus-eluting stent (EES) vs. cobalt chromium bare metal stent (BMS) in STEMI patients. It included 1498 patients, randomized to EES (n ¼751) or BMS (n¼747). Results: At 1-year, definite/probable stent thrombosis, defined according to ARC criteria, occurred in 26 patients (1.73%), including 18 definite and 8 probable. Prospective, randomized clinical trials have shown that in-stent restenosis is reduced by the use of drug-eluting stents, as compared with bare-metal stents. 1,2 On the basis of prospective trials.

Restenosis: Definition, Symptoms, In-Stent Thrombosis, and

January 30, 2014—A study comparing standard balloon angioplasty versus angioplasty with a paclitaxel-eluting balloon for femoral artery in-stent restenosis was presented by principal investigator Hans Krankenberg, MD, at LINC 2014: the Leipzig Interventional Course in Leipzig, Germany.Dr In-stent thrombosis most commonly pre- sents acutely, with a . 70% incidence of myocardial infarction and . 25% of death. In the case presented here, both the clinical presentation and the angiographic pattern were more consistent with a type III-IV in- stent restenosis, but (late) in-stent throm- bosis might have mimicked this angio- graphic. Thus, mortality due to stent thrombosis has been reported to be as high as 45 % (3). Definition and classification. A new standard definition of stent thrombosis was recently proposed by an Academic Research Consortium (ARC) in order to make it possible to compare the true rates of stent thrombosis across different trials and registries (4) Dr Raghu Kolluri (OhioHealth, Columbus, OH, US) shares the results from a study comparing patients with in-tack restenosis VS. in-stent restenosis

problem of in-stent restenosis, the Achilles' heel of bare-metal stents (BMS). Randomized trials have dem-onstrated the superior efficacy of DES in terms of reste-nosis1,2 but has raised a new concern over the potential for late and very late stent thrombosis (ST), a phenom-enon that was not previously recognized with BMS. Stent thrombosis has been associated with high rates of morbidity and mortality, often leading to events of cardiac death or nonfatal myocardial infarction (MI). When compared to in-stent restenosis, which leads to anginal type symptoms, stent thrombosis is typically an acute process resulting in acute coronary syndrome (ACS) Despite major improvements in antiplatelet therapy, thrombotic events remain the primary cause of death after percutaneous coronary interventions. 1,2 Sirolimus-eluting stents and polymer-based paclitaxel-eluting stents have been shown to reduce neointimal hyperplasia and risk of restenosis without increasing the risk of stent thrombosis. 3-7. No stent thromboses occurred in either stent between two and three years, and there were no differences in overall rates of stent thrombosis between the two stents (0.9 versus 1.6%; p=0.37). However, SPIRIT IV found a statistically significant difference in stent thrombosis between the two arms at one year: 0.29% for Xience V versus 1.06% for. A nanocoated coronary stent system delivers favorable results in terms of target vessel failure, restenosis and stent thrombosis events vs. traditional bare-metal stents, according to results from.

Drug-eluting stents were developed to lower the rate of restenosis, which now occurs in less than 10 percent of patients treated with these stents. There have been concerns about abrupt thrombosis. This is the problem of restenosis — recurring blockage at the site of treatment. In the early 2000s, brachytherapy, or coronary artery radiation therapy, became a promising new treatment for restenosis. But while brachytherapy was (and still is) quite effective for restenosis, it now has been largely supplanted by the use of drug-eluting stents

Stent thrombosis was similar in both arms at 0.6% and 0.8% respectively. Angiographic restenosis in the stent at nine months was reduced from 35.4% to 3.2%, and angiographic restenosis in the analysis segment was reduced from 36.3% to 8.9% A case of very late stent thrombosis after second-generation drug-eluting stent implantation. a At 5-year follow-up, coronary angiography shows a moderate restenosis within a everolimus-eluting stent 3.0 × 23 mm (yellow line).b Four month later, very late stent thrombosis occurs.c-g The sequence of five optical coherence tomography (OCT) image slices with 1.0-mm intervals from distal (c) to. We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting stents (PES) should be preferred for the treatment of DM patients. A systematic search of publications about randomized controlled trials (RCTs) focused on diabetic patients received EES, SES or PES was conducted The 1-year rates of myocardial infarction and stent thrombosis were also lower with everolimus-eluting stents than with paclitaxel-eluting stents (1.9% vs. 3.1%, P=0.02 for myocardial infarction.

CAD: In-Stent Restenosis - Cleveland Clini

TCT-477 TCT-479 Clinical characteristics, procedural and clinical outcome of patients treated with PCI for definitive stent thrombosis: a 12 years single centre experience Impact of Angiographic Patterns (Focal vs. Diffuse) of Resistant In-stent Restenosis on Clinical Outcomes Eduard Fernandez-Nofrerias1, Oriol Rodriguez-Leor1, Xavier. Restenosis is clinically silent in approximately half the patients and usually presents as a recurrence of angina. Also of concern is the issue of stent thrombosis (ST), which although less common than restenosis, causes far more serious clinical events including myocardial infarction and death thrombosis and restenosis. Types of stent coatings There is a variety of stent coatings with differ-ing performance profiles that have been studied either in animal studies or clinical trials. The stent coatings can be broadly classified into three types: biocompatible coatings, drug-deliver

DES STENT >>>> BMS -ISR The ISAR-DESIRE (Intracoronary Stenting or Angioplasty for Restenosis Reduction-Drug-Eluting Stents for In-Stent Restenosis) trial was the first randomized study assessing the value of DES in patients with BMS-ISR. 300 patients were randomly allocated to treatment with sirolimus-DES, paclitaxel-DES, or BA loon versus regular balloon for in-stent restenosis in stent graft. We plan to enroll 40 patients who presented with prosthetic AVG in-stent restenosis, and then to evaluate the restenosis lesions with intravascular ultrasound. Patients will be randomized into two groups of treatment: drug-coated balloon angioplasty or regular balloo Bare-metal stents (BMS) have the drawback of higher rates of in-stent restenosis (ISR); however, drug-eluting stents (DES) have a worrying rate of stent thrombosis, a more acute and unpredictable. Six adverse events (5 thrombosis and 1 restenosis) were associated with grade V fracture (67%), while there were no fracture site-related adverse pathologic findings in stents with grades I to IV fracture except for one stented lesion with grade IV which had a long overlapping stent (grade I-IV versus grade V, )

Stent Thrombosis With Ticagrelor Versus Clopidogrel in

In-stent restenosis and stent thrombosis remain important limitations of the current PCI practice. Besides the procedure-related risk factors and medication, solid evidence demonstrated that a patient's own response to stent implantation influences the outcome. Individual genetic responses involve inflammation, cellular proliferation. Notes for editors 1. Sarno G, Lagerqvist B, Frober O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the. Excimer laser coronary atherectomy is indicated for handling thrombosis and in-stent restenosis, and combined with drug-coated balloons may also be a good choice to address VLST caused by in-stent neoatherosclerosis. 76-78. Optimized Antiplatelet Therapy Restenosis. Restenosis is the reduction in the diameter of the vessel lumen after angioplasty 1).Despite advances in stent technology, restenosis continues to be the most frequent cause of target lesion failure following percutaneous coronary intervention 2).Following the introduction of bare-metal stents in the mid-1990s for the treatment of coronary artery disease, a new clinical entity.

Stent failure, comprised of in-stent restenosis (ISR) and stent thrombosis (ST), is a well-known complication of percutaneous stent implantation [1•].The factors associated with ISR include neointimal hyperplasia, neoatherosclerosis (NA), stent fracture, and stent underexpansion [2, 3], while risk of ST is associated with suboptimal stent deployment, including inappropriate stent sizing. Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis (RESTORE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial. J Am Coll Cardiol 2015;66:23-33 The aim of this study was to evaluate the inhibitory effect of sirolimus coating on the occurrence of restenosis and thrombosis with heparinized stents. Heparin and dopamine were conjugated by chem.. Restenosis is a serious occurrence that can lead not only to recurrent angina and repeat revascularisation but also to acute coronary syndromes. Drug-eluting stents revolutionised interventional cardiology owing to their pronounced ability to reduce restenosis compared with bare-metal stents. Attention has now shifted to safety of these devices because of evidence suggesting an association.

Late stent thrombosis has been a concern for interventional cardiologists since the early days of drug-eluting stent (DES) technology. Although the problem did not appear common, a series of angiographically documented late stent thromboses from the Thoraxcenter Rotterdam was published in 2004, sounding a cautionary, albeit non-alarmist, note. 1 In 2005, a prospective observational cohort. Read Late thrombosis following treatment of in‐stent restenosis with drug‐eluting stents after discontinuation of antiplatelet therapy, Catheterization and Cardiovascular Interventions on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips Paclitaxel-eluting balloon vs standard angioplasty to reduce restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: three-year results of the DEBATE-ISR Study. J Endovasc Ther Background: Stent thrombosis (ST) is a dreaded complication after stent implantation and is associated with a mortality between 5% and 45%.The mechanisms by which ST arises are complex. Because of.

Comparison of Thrombosis and Restenosis Risk from Stent

  1. Furthermore, the risk of early and 1-year definite or probable stent thrombosis remained reduced for CoCr-EES versus bare-metal stents, even after the EXAMINATION trial was removed from the meta-analysis (OR 0·31, 95% CI 0·14-0·63, for early thrombosis and 0·34, 0·19-0·57, for 1-year thrombosis)
  2. Prevention of stent thrombosis: challenges and solutions Risheen Reejhsinghani, Amir S LotfiDivision of Cardiology, Baystate Medical Center, Springfield, MA, USAAbstract: Stent thrombosis is an uncommon but serious complication which carries with it significant mortality and morbidity. This review analyzes the entity of stent thrombosis from a historical and clinical perspective, and.
  3. Palmerini T, et al. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. Lancet 2012. Bangalore S, et al. Short- and Long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117,762 patient-years of follow-up from randomized trials
  4. OBJECTIVES We compared intravascular ultrasound findings of drug-eluting stent (DES)-treated lesions that developed thrombosis versus in-stent restenosis (ISR). BACKGROUND Stent underexpansion is a predictor of both DES thrombosis and ISR. However, all underexpanded DES may not be equal. METHODS Intravascular ultrasound findings from 20 definite DES thrombosis patients (representing all.

New-Generation DES Reduce Restenosis, Stent Thrombosis

Mehilli J, Byrne RA, Tiroch K, et al. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study The intimal reaction to the stent as a foreign body can also cause thrombosis within the stent, which, together with the inflammatory reaction, can bring about in-stent restenosis

in-stent restenosis and thrombosis, which may obstruct the flow through the stent. Thrombosis. The frequency of in-stent thrombosis is low, with a cumulative incidence of 1.3%-1.7% at 9-month follow-up (20). However, even this incidence is clinically important because in-stent thrombosis is associated with high mortality and morbidit Longitudinal stent deformation (LSD) has gained more attention recently. To date, the clinical implications of LSD have been uncertain [1,2,3].Theoretically, LSD could result in metal overload, malapposition, incomplete plaque coverage and reduced drug delivery, which may lead to a higher risk of stent thrombosis and in-stent restenosis (ISR) [2, 4] Stent Thrombosis Risk Lower with Xience vs. First-Generation DES. Newer-generation everolimus-eluting stents (EES) are associated with a lower risk of stent thrombosis—in particular very late stent thrombosis—compared with older sirolimus- and paclitaxel-eluting stents (SES and PES), according to observational data published online February. Rate of stent thrombosis in 3rd tertile was significantly higher than other tertiles (41% vs 38% vs 58%, respectively; P = 0.006) . There was no significant difference about type of stent thrombosis between tertiles (acute, subacute, late, and very late) Data expressed are mean value ± SD. Maximal in-stent tissue growth, In-stent intimal hyperplasia at the maximal site at follow-up. *P .05 versus GFX stent. †P .01 versus GFX stent. Discussion This study shows that a Multilink stent is more favorable with regard to neointimal hyperplasia and restenosis rate compared with a GFX stent

Cardiovascular stenting is an effective method for treating cardiovascular diseases (CVDs), yet thrombosis and restenosis are the two major clinical complications that often lead to device failure. Nitric oxide (NO) has been proposed as a promising small molecule in improving the clinical performance of cardiovascular stents thanks to its anti-thrombosis and anti-restenosis ability, but its. Drug-Eluting Stent ISAR-DESIRE 2: TLR Stent thrombosis: SES 6.3% vs. PES 6.1% (p = 0.98) Byrne, R, TCT 200 Aims: The aim of this study was to investigate clinical outcomes of patients at high risk of restenosis after implantation of a bioresorbable vascular scaffold (BVS). Conclusions: In patients at high risk of restenosis, non-inferiority of BVS compared with EES in terms of TLF was met at one year. BVS carried a higher risk of device thrombosis and TVMI than EES

Antiplatelet Therapy in the Era of Drug-Eluting StentsCoronary restenosis after stent implantation

Thrombosis After Stent Implantation: How Much of a Problem

ment of In-Stent Restenosis (TIS) trial was single centre, and the others were multicentre. Patients enrolled were from Czech in the TIS trial, Spain in the Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs. Everolimus-eluting Stent (RIBS) IV and RIBS V trials, Belgium in the Safety and Efficacy of a Drug eIUtin Coronary heart disease is a major cause of death and disability in developed countries. Stent implantation has become an efficacious treatment for a culprit lesion vessel of the coronary artery. However, 10%-20% restenosis is still an important complication that restricts the clinical safety and efficacy of drug-eluting stents Most patients (15.5%) had non-ST-segment elevation MIs, but 7.8% had STEMIs, with stent restenosis being the culprit, which means the patient has restenosis, but they also have an overlying acute thrombosis, he said. The study was published in The Journal of the American College of Cardiology On average, stents appear to have a 10% lower rate of restenosis compared with angioplasty and the favuorable results due to stent usage have been reported in several studies. 5 Unfortunately, stents have an inherent rate of restenosis of 10-60%. 6- 8 The risk factors of restenosis include the method (stented or not), lesion location (the.

UpToDat

  1. Introduction. Early-generation drug-eluting stents (DES), sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) appeared to be very effective at reducing the rates of restenosis and target lesion revascularisation compared with bare metal stents.1-4 However, stent thrombosis (ST), which causes acute coronary obstruction and could lead to myocardial infarction (MI) or sudden.
  2. Overlapping stents, excessive stent length and stents at bifurcations, or history of previous in-stent restenosis or thrombosis, may indicate a high risk for thrombosis.16 18 Complex stent anatomy may be a more important risk factor for MI caused by arterial thrombus than just coronary artery disease or prior stents alone. For patients with.
  3. 3 Failing stents: thrombosis vs restenosis. Schuchman, New Engl J Med 2006. 4 Stent thrombosis in the medical literature. Google Scholar searched for stent AND thrombosis on 8 June 2010. 5 History of stent thrombosis. IMPACT OF DUAL ANTIPLATELET THERAPY AND HIGH PRESSURE DILATION
Restenosis After Angioplasty and Stenting

Stent Thrombosis - The Cardiology Adviso

In stratified analyses, the reduction of risk of restenosis with the sirolimus-eluting stent in comparison with the uncoated stent was independent of sex, diabetes mellitus status, clinical presentation (acute coronary syndrome vs chronic stable angina or silent myocardial ischemia), epicardial vessel location, stent diameter, and stent length The rate of stent thrombosis was 1.7% in patients with DES vs. 2.6% in patients with BMS (weighted risk difference, -1.05%; P for noninferiority<.001; P for difference=.01), Kereiakes, medical. Definite Stent Thrombosis. 1) Angiographic confirmation of stent thrombosis: The presence of intracoronary thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent and presence of at least 1 of the following criteria within a 48-hour time window: Nonocclusive thrombus -Intracoronary thrombus is defined as a. A total of 5030 patients were included in the present analysis. The rate of stent thrombosis was 0.58% in the drug-eluting stent group (n = 15)and 0.54% (n = 13) in the bare metal stent arm (Figure 1). Figure 1. Stent thrombosis: drug-eluting stents vs bare metal stents. Analysis according to the time of the stent thrombosis yielded similar. March 14, 2013 -- San Francisco -- Important news for stent patients and cardiologists alike: data from a new analysis of Medtronic's (NYSE: MDT) RESOLUTE global drug-eluting stent program show very low occurrence of stent thrombosis when dual antiplatelet therapy (DAPT) is interrupted or discontinued after one month. Current U.S. guidelines and Instructions For Use (IFU) for all drug- eluting.

Peripheral Vascular Diseas

  1. Really important to reduce restenosis, understanding expansion ranges in stent length, understanding the stent complications such as restenosis, 10 thrombosis, launching, launching a stent in formation and tissue prolapse and then focusing on vessel preparation and calcium treatment critical
  2. This promised to solve the spectre of in-stent restenosis (ISR) completely by preventing early tissue formation after stent deployment. These improvements have certainly led to superior results with reduced target lesion failure and target lesion revascularisation, MI and stent thrombosis when compared with BMS or the earlier generation of DES. 8,
  3. CONCLUSIONS In a multicenter peripheral interventional registry, femoropopliteal ST occurred in 4.3% of patients who underwent stent procedures, and it was associated with treatment of chronic total occlusions and in-stent restenosis lesions, and had higher 12-month major adverse limb events
  4. A relatively uncommon adverse event, stent thrombosis, occurs in about 0.6% of patients per year. 6 Stent thrombosis is the formation of a clot at the site of stent placement. When it occurs, it may occlude the artery and cause death in as many as 45% of patients. 10 Stent thrombosis usually occurs early (within 30 days of stent placement) or.
  5. The 6-month restenosis rate was correspondingly lower with radiation (21% vs. 44%), resulting in a lower 12-month rate of target-vessel revascularization (28% vs. 62%). Only 1 radiation recipient (vs. 3 placebo patients) developed late thrombosis, despite additional stenting in 50% of patients overall
  6. Background Good results of drug-eluting balloon (DEB) use are achieved in in-stent restenosis (ISR) lesions, small vessel disease, long lesions, and bifurcations. However, few reports exist about DEB use in acute myocardial infarction (AMI) with ISR. This study's aim was to evaluate the efficacy of DEB for AMI with ISR. Methods Between November 2011 and December 2015, 117 consecutive.
Restenosis and Stent Thrombosis | tctmdTips and Tricks for Venous IVUS Success - Endovascular TodaySESAMI: Sirolimus Stent vs Bare Stent in Acute Myocardial

Cite this article as: Akhtar M, Liu W. Use of intravascular ultrasound vs. optical coherence tomography for mechanism and patterns of in-stent restenosis among bare metal stents and drug eluting stents. J Thorac Dis 2016;8(1):E104-E108. doi: 10.3978/j.issn.2072-1439.2016.01.4 In terms of safety outcomes, the rates of death/myocardial infarction (6.1% vs. 5.8%; p = 0.86) and stent thrombosis (0.4% vs. 0.4%; p>0.99) were also similar. CONCLUSIONS: In cases of SES restenosis, treatment with either repeat SES or switch to PES was associated with a comparable degree of efficacy and safety However, the prevalence of HTPR in Chinese patients with AMI or coronary artery in-stent restenosis (ISR) and the beneficial impact of ticagrelor compared with high-dose clopidogrel in overcoming. late stent thrombosis: Cardiology The scar-induced closure of a previously stenosed coronary artery, a complication in ±20% of Pts who have undergone stenting for CAD. See Stent . Cf In-stent restenosis / Prospective randomized comparison of clinical and angiographic outcomes between everolimus-eluting vs. zotarolimus-eluting stents for treatment of coronary restenosis in drug-eluting stents:Intravascular ultrasound volumetric analysis (RESTENT-ISR trial). In: European heart journal. 2016 ; Vol. 37, No. 45. pp. 3409-3418 Stent thrombosis is one of the most feared complications of percutaneous coronary intervention. Most commonly it occurs within the first few days after the deployment of the stent. Once the stent is completely endothelialized, this complication becomes extremely rare. Few cases of very late stent thrombosis were reported in the literature with the longest interval being around 11 years after.